Literature DB >> 19525854

Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.

Vladimir Novitsky1, Rui Wang, Lemme Kebaabetswe, Jamieson Greenwald, Raabya Rossenkhan, Sikhulile Moyo, Rosemary Musonda, Elias Woldegabriel, Stephen Lagakos, M Essex.   

Abstract

BACKGROUND: Estimation of HIV incidence rates is important for timing interventions, planning prevention studies, and monitoring the epidemic. This requires accurate estimation of the "recency period" (also known as the "window period") between seroconversion and achievement of specific detectable levels of anti-HIV antibody titers, such as the standardized optical density (SOD) in the early phase of HIV-1 infection.
METHODS: To obtain a better understanding of interpatient variation of the recency period, prospective measurements of antiviral antibody titers in the early phase of HIV-1 subtype C infection were quantified by Vironostika-LS. Time of seroconversion was estimated by Fiebig staging.
RESULTS: The profiles of SOD values during the first year of infection commonly showed slow initial increase followed by a more rapid increase, although in some patients, SOD values increased rapidly soon after seroconversion. Using an SOD cutoff of 1.0, the average duration of the recency period in subtype C infection in the local epidemic in Botswana was estimated to be 151 days (95% confidence interval: 130 to 172 days) post seroconversion. The recency period was significantly associated (P = 0.007) with the level of viral replication during the first 2-3 months post seroconversion. Reduction of SOD values after initiation of antiretroviral therapy (ART) was a dominant pattern in antiretroviral drug (ARV)-treated subjects.
CONCLUSIONS: Our data suggest that HIV incidence estimation based on sensitive/less sensitive enzyme immunoassay cross-sectional testing could be potentially improved by incorporation of viral load levels at the time of detection of a recent infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525854      PMCID: PMC2815186          DOI: 10.1097/QAI.0b013e3181ab6ef0

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  28 in total

1.  Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).

Authors:  M K Morris; D A Katzenstein; D Israelski; A Zolopa; R M Hendry; C V Hanson
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-15       Impact factor: 3.731

2.  Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.

Authors:  Denise Kothe; Robert H Byers; Samuel P Caudill; Glen A Satten; Robert S Janssen; W Harry Hannon; Joanne V Mei
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

3.  Direct and indirect estimates of HIV-1 incidence in a high-prevalence population.

Authors:  F R Cleghorn; N Jack; J R Murphy; J Edwards; B Mahabir; R Paul; T O'Brien; M Greenberg; K Weinhold; C Bartholomew; R Brookmeyer; W A Blattner
Journal:  Am J Epidemiol       Date:  1998-05-01       Impact factor: 4.897

4.  Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method.

Authors:  Barbara Suligoi; Claudio Galli; Mario Massi; Fiorella Di Sora; Mauro Sciandra; Patrizio Pezzotti; Olga Recchia; Francesco Montella; Alessandro Sinicco; Giovanni Rezza
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  Viral load differences in early infection with two HIV-1 subtypes.

Authors:  D J Hu; S Vanichseni; T D Mastro; S Raktham; N L Young; P A Mock; S Subbarao; B S Parekh; L Srisuwanvilai ; R Sutthent; C Wasi; W Heneine; K Choopanya
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

6.  Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection.

Authors:  Bhupat D Rawal; Azucena Degula; Ludmila Lebedeva; Robert S Janssen; Frederick M Hecht; Haynes W Sheppard; Michael P Busch
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

7.  Evaluation of a sensitive/less sensitive testing algorithm using the bioMérieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand.

Authors:  Carrie L Young; Dale J Hu; Robert Byers; Suphak Vanichseni; Nancy L Young; Robert Nelson; Philip A Mock; Kachit Choopanya; Robert Janssen; Timothy D Mastro; Joanne V Mei
Journal:  AIDS Res Hum Retroviruses       Date:  2003-06       Impact factor: 2.205

8.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests.

Authors:  R Brookmeyer; T C Quinn
Journal:  Am J Epidemiol       Date:  1995-01-15       Impact factor: 4.897

10.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

Authors:  R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  23 in total

1.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Authors:  Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

3.  Dynamics and timing of in vivo mutations at Gag residue 242 during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Sikhulile Moyo; Rosemary Musonda; M Essex
Journal:  Virology       Date:  2010-05-04       Impact factor: 3.616

4.  Genome-Wide Analyses Reveal Gene Influence on HIV Disease Progression and HIV-1C Acquisition in Southern Africa.

Authors:  Wen Xie; Denis Agniel; Andrey Shevchenko; Sergey V Malov; Anton Svitin; Nikolay Cherkasov; Marianna K Baum; Adriana Campa; Simani Gaseitsiwe; Hermann Bussmann; Joseph Makhema; Richard Marlink; Vladimir Novitsky; Tun-Hou Lee; Tianxi Cai; Stephen J O'Brien; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-06       Impact factor: 2.205

5.  Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward.

Authors:  Timothy D Mastro; Andrea A Kim; Timothy Hallett; Thomas Rehle; Alex Welte; Oliver Laeyendecker; Tom Oluoch; Jesus M Garcia-Calleja
Journal:  J HIV AIDS Surveill Epidemiol       Date:  2010-01-01

6.  Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.

Authors:  Rui Wang; Jia Weng; Sikhulile Moyo; Debanjan Pain; Christopher D Barr; Dorcas Maruapula; Dineo Mongwato; Joseph Makhema; Vladimir Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-19       Impact factor: 2.205

7.  HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.

Authors:  Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

8.  On the use of adjusted cross-sectional estimators of HIV incidence.

Authors:  Rui Wang; Stephen W Lagakos
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

9.  Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Zabrina L Brumme; Craig A Magaret; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; Paul T Edlefsen; Vlad Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2016-07-26       Impact factor: 2.205

10.  Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Lemme Kebaabetswe; Raabya Rossenkhan; Caitlin Bonney; Michaela Herzig; David Nkwe; Sikhulile Moyo; Rosemary Musonda; Elias Woldegabriel; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.